Abbott Laboratories
ABTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. The $178.55B market capitalization puts ABT squarely in large-cap range for its industry. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Market Cap
$178.55B
Beta
—
P/E (TTM)
38.11
P/E (Fwd)
17.20
EPS (TTM)
$2.69
EPS (Fwd)
$5.96
ROE
—
ROA
—
Cash
—
Total Debt
—
Free CF
—
52W Change
-18.9%
Annual Financials
Cash vs Debt
Where ABT stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, ABT finished 4.70% above its 150-day moving average ($98.35) and 0.72% above its 200-day moving average ($102.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABT overbought or oversold?
At the October 15, 2026 close, ABT's RSI(14) was 56.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
As with any equity investment, ABT carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Abbott Laboratories and its sector.